|
業務類別
|
Biotechnology |
|
業務概覽
|
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia. |
| 公司地址
| 4275 Executive Square, Suite 300, La Jolla, CA, USA, 92037 |
| 電話號碼
| +1 858 373-1500 |
| 傳真號碼
| +1 858 404-0048 |
| 公司網頁
| https://www.medicinova.com |
| 員工數量
| 6 |
| Dr. Yuichi Iwaki,M.D.,PhD |
Chairman of the Board, President and Chief Executive Officer |
美元 657.38K |
29/04/2026 |
| Dr. Kazuko Matsuda, M.D.,M.P.H.,PhD |
Director, Senior Vice President and Chief Medical Officer |
美元 514.42K |
29/04/2026 |
| Mr. David H. Crean, PhD |
Chief Business Officer |
美元 120.00K |
29/04/2026 |
| Mr. Jason J. Kruger |
Chief Financial Officer and Principal Accounting Officer |
-- |
29/04/2026 |
|
|
| Dr. Yuichi Iwaki,M.D.,PhD |
Chairman of the Board, President and Chief Executive Officer |
29/04/2026 |
| Ms. Carolyn D. Beaver, C.P.A. |
Independent Director |
29/04/2026 |
| Mr. Hideki Nagao |
Independent Director |
29/04/2026 |
| Dr. Kazuko Matsuda, M.D.,M.P.H.,PhD |
Director, Senior Vice President and Chief Medical Officer |
29/04/2026 |
| Ms. Nicole Lemerond |
Independent Director |
29/04/2026 |
|
|
|
|
